Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:RCKT

Rocket Pharmaceuticals Q3 2026 Earnings Date & Estimates

Rocket Pharmaceuticals logo
$2.56 -0.07 (-2.66%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$2.58 +0.02 (+0.86%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rocket Pharmaceuticals is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Rocket Pharmaceuticals in Q3 2026

Rocket Pharmaceuticals is expected to post earnings of -$0.39 per share on revenue of $0.20 million. In the same quarter a year earlier Rocket Pharmaceuticals reported -$0.45 per share. Rocket Pharmaceuticals last reported on August 10, 2026, posting $1.08 per share and beating the $0.86 consensus estimate. Rocket Pharmaceuticals has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.39
Expected Revenue
$0.20 million
Prior-Year EPS
-$0.45

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$1.08 (Beat by +$0.22)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Rocket Pharmaceuticals Q3 2026 Earnings FAQ

Rocket Pharmaceuticals (NASDAQ:RCKT) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Rocket Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Rocket Pharmaceuticals to post earnings of -$0.39 per share for Q3 2026.

The consensus revenue estimate for Rocket Pharmaceuticals is $0.20 million for Q3 2026.

Rocket Pharmaceuticals Earnings Headlines

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock Has Average Price Target of $7.77 According to Brokerages
October 10 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104861
Rocket Pharmaceuticals Inc (RCKT)
October 9 at 2:36 PM  |  za.investing.comhttps://za.investing.com/equities/inotek-pharmaceuticals-corp-news/30
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
October 11 at 1:00 AM  |  Stansberry Research (Ad)
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)
October 9 at 9:36 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VKTX/pressreleases/5065945/analysts-are-bullish-on-these-healthcare-stocks-viking-therapeutics-vktx-rocket-pharmaceuticals-rckt/
Wedbush Reaffirms "Outperform" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)
October 9 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101594
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Target Cut by Leerink Partners
October 9 at 1:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101246
See More Rocket Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rocket Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rocket Pharmaceuticals and other key companies, straight to your email.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals (NASDAQ:RCKT) (NASDAQ:RCKT) is a biotechnology company focused on developing gene therapies for rare and devastating diseases. The company uses both ex vivo hematopoietic stem cell gene therapy and in vivo adeno-associated virus (AAV) gene therapy approaches to address conditions with limited or no effective treatment options.

Rocket’s development programs have included marnetegragene autotemcel (RP-L102) for leukocyte adhesion deficiency-I, a rare inherited immune disorder; RP-A501 for Danon disease, a genetic heart condition; RP-A601 for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 mutations; and RP-L301 for pyruvate kinase deficiency, an inherited blood disorder. The company’s pipeline has also included additional programs targeting rare cardiovascular, hematologic and metabolic diseases.

Founded in 2015 and headquartered in Cranbury, New Jersey, Rocket conducts research and clinical development through global programs and collaborations. The company is led by Chief Executive Officer Gaurav Shah, M.D., who has overseen its expansion as a developer of genetic medicines for patients with serious rare diseases.

View Rocket Pharmaceuticals Profile
Earnings Tools